Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
Status:
RECRUITING
Trial end date:
2031-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant pancreatic ductal adenocarcinoma. These are subjects who have not previously been treated with anthracyclines.